title: Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
abstract: Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.
authors.affiliation: Seattle Children's Hospital, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA 98106, USA. julie.park@seattlechildrens.org
authors.forename: Julie R
authors.initials: JR
authors.lastname: Park
authors.forename: Rochelle
authors.initials: R
authors.lastname: Bagatell
authors.forename: Wendy B
authors.initials: WB
authors.lastname: London
authors.forename: John M
authors.initials: JM
authors.lastname: Maris
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
authors.forename: Katherine K
authors.initials: KK
authors.lastname: Mattay
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Mattay
authors.forename: Michael
authors.initials: M
authors.lastname: Hogarty
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D009447:Neuroblastoma / Q000628:therapy*; D012106:Research; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents